Fig. 1From: A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metforminStudy design; T2D = type 2 diabetes mellitus; q.w. = once weekly; R = randomization; q.d. = once dailyBack to article page